The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease

被引:0
|
作者
Lee, Ju Kwang [1 ]
Kim, Seonok [2 ]
Chong, Yong Pil [3 ]
Lee, Hyun Joo [4 ]
Shim, Tae Sun [5 ]
Jo, Kyung-Wook [5 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea
[5] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
all-cause mortality; cavitary type; Mycobacterium avium complex; treatment outcome; TREATMENT OUTCOMES; LUNG-DISEASE; TUBERCULOSIS;
D O I
10.1016/j.chest.2024.03.027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: The association between treatment outcome and the mortality of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) with cavitary lesions is unclear. This article assessed the impact of culture conversion on mortality in patients with cavitary RESEARCH QUESTION: Is the achievement of sputum culture conversion in patients with MAC-PD with cavitary lesions associated with the prognosis? STUDY DESIGN AND METHODS: From 2002 to 2020, a total of 351 patients with cavitary MAC-PD (105 with the fibrocavitary type and 246 with the cavitary nodular bronchiectatic type), who had been treated with a >= 6-month macrolide-containing regimen at a tertiary referral center in South Korea, were retrospectively enrolled in this study. All-cause mortality during the follow-up period was analyzed based on culture conversion at the time of treatment completion. RESULTS: The cohort had a median treatment duration of 14.7 months (interquartile range [IQR], 13.4-16.8 months). Of the 351 patients, 69.8% (245 of 351) achieved culture conversion, and 30.2% (106 of 351) did not. The median follow-up was 4.4 years (IQR, 2.3-8.3 years) in patients with culture conversion and 3.1 years (IQR, 2.1-4.8 years) in those without. For the patients with and without culture conversion, all-cause mortality was 5.3% vs 35.8% (P < .001), and the 5-year cumulative mortality was 20.0% vs 38.4%, respectively. Cox analysis found that a lack of culture conversion was significantly associated with higher mortality (adjusted hazard ratio, 5.73; 95% CI, 2.86-11.50). Moreover, the 2-year landmark analysis revealed a distinct impact of treatment outcome on mortality. INTERPRETATION: The mortality rate of patients with cavitary MAC-PD who did not achieve culture conversion was significantly higher than that of those with culture conversion.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 50 条
  • [1] Influence Of Environmental Exposures On Sputum Culture Conversion In Untreated Pulmonary Mycobacterium Avium-Intracellulare Complex Disease
    Ito, Y.
    Hirai, T.
    Fujita, K.
    Maekawa, K.
    Kubo, T.
    Togashi, K.
    Ichiyama, S.
    Mishima, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [2] Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease
    Kim, Ock-Hwa
    Kwon, Byoung Soo
    Han, Minkyu
    Koh, Younsuck
    Kim, Woo-Sung
    Song, Jin-Woo
    Oh, Yeon-Mok
    Lee, Sang-Do
    Lee, Sei Won
    Lee, Jae-Seung
    Lim, Chae-Man
    Choi, Chang-Min
    Huh, Jin-Won
    Hong, Sang-Bum
    Shim, Tae Sun
    Jo, Kyung-Wook
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (11) : 1870 - 1876
  • [3] CULTURE CONVERSION AND MORTALITY IN PATIENTS WITH MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE: A SYSTEMATIC REVIEW
    Flume, Patrick
    Mange, Kevin
    Jumadilova, Zhanna
    Cline, Kristan
    Winthrop, Kevin
    CHEST, 2020, 158 (04) : 312A - 312A
  • [4] Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease
    Kim, Ock-Hwa
    Kwon, Byoung Soo
    Koh, Younsuck
    Kim, Woo-Sung
    Song, Jin-Woo
    Oh, Yeon-Mok
    Lee, Sang-Do
    Lee, Sei Won
    Lee, Jae-Seung
    Lim, Chae-Man
    Choi, Chang-Min
    Huh, Jin-Won
    Hong, Sang-Bum
    Shim, Tae Sun
    Jo, Kyung-Wook
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [5] Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease
    Okumura, Masao
    Iwai, Kazuro
    Ogata, Hideo
    Ueyama, Masako
    Kubota, Motoko
    Aoki, Misako
    Kokuto, Hiroyuki
    Tadokoro, Eiji
    Uchiyama, Takashi
    Saotome, Mikio
    Yoshiyama, Takashi
    Yoshimori, Kouzou
    Yoshida, Naoyuki
    Azuma, Arata
    Kudoh, Shoji
    INTERNAL MEDICINE, 2008, 47 (16) : 1465 - 1472
  • [6] Efficacy of three sputum specimens for the diagnosis of Mycobacterium avium complex pulmonary disease
    Naohisa Urabe
    Susumu Sakamoto
    Marie Masuoka
    Chiaki Kato
    Asuka Yamaguchi
    Nozomi Tokita
    Sakae Homma
    Kazuma Kishi
    BMC Pulmonary Medicine, 23
  • [7] Efficacy of three sputum specimens for the diagnosis of Mycobacterium avium complex pulmonary disease
    Urabe, Naohisa
    Sakamoto, Susumu
    Masuoka, Marie
    Kato, Chiaki
    Yamaguchi, Asuka
    Tokita, Nozomi
    Homma, Sakae
    Kishi, Kazuma
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [8] Association between Mycobacterium tuberculosis lineage and time to sputum culture conversion
    Click, E. S.
    Winston, C. A.
    Oeltmann, J. E.
    Moonan, P. K.
    Mac Kenzie, W. R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (07) : 878 - 884
  • [9] Isolated cavitary pulmonary Mycobacterium avium complex infection in a patient with AIDS
    Alisky, JM
    Schlesinger, L
    CLINICAL INFECTIOUS DISEASES, 1998, 27 (06) : 1542 - 1543
  • [10] Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients
    Deshpande, Devyani
    Magombedze, Gesham
    Boorgula, Gunavanthi D.
    Chapagain, Moti
    Srivastava, Shashikant
    Gumbo, Tawanda
    JOURNAL OF INFECTIOUS DISEASES, 2023, 230 (02): : e230 - e240